Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

AstraZeneca has been boosted by results from ASCO which show its Lynparza could expand its use beyond ovarian cancer. Results from a phase 3 trial presented today showed that patients treated with ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co ...

After hours: September 23 at 7:49 PM EDT Loading Chart for AZN ...

After hours: 20 September at 19:57 GMT-4 ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.